Meeting
2011 ASCO Annual Meeting
Incidence of febrile neutropenia with docetaxel plus cyclophosphamide in a university-based breast oncology clinic.
Authors
A. Soni
University of Pittsburgh Medical Center, Magee-Womens Cancer Program, Pittsburgh, PA
A. Soni , A. Brufsky , R. C. Jankowitz , P. Rastogi , V. G. Vogel , S. Puhalla
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Supportive Care
Citation
J Clin Oncol 29: 2011 (suppl; abstr 9061)
Abstract #
9061
Poster Bd #
44D
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Quality Care Symposium
Association of primary prophylactic (PP) granulocyte-colony stimulating factor (G-CSF) use with chemotherapy dose modifications and relative dose intensity (RDI) among breast cancer patients receiving high-risk regimens for febrile neutropenia (FN).
First Author: Jaime Shaw
Poster
2012 Breast Cancer Symposium
Adjuvant chemotherapy for early-stage breast cancer: Choice of regimen and associated hematologic toxicities in a metropolitan Australian hospital.
First Author: Katherine Lovat
Poster
2020 ASCO Quality Care Symposium
Cost-effectiveness of filgrastim-sndz as primary prophylaxis (PP) versus secondary prophylaxis (SP) to prevent chemotherapy-induced febrile neutropenia (FN) in breast cancer patients at intermediate risk.
First Author: Edward C. Li
Poster
2013 ASCO Annual Meeting
A multicenter audit of the incidence of febrile neutropenia and neutropenia associated with docetaxel and cyclophosphamide (TC) chemotherapy for early breast cancer.
First Author: Roopa Lakhanpal